tiprankstipranks
Advertisement
Advertisement
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
PremiumCompany AnnouncementsQyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
2M ago
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
Premium
Company Announcements
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
2M ago
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
Premium
Company Announcements
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
2M ago
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
PremiumCompany AnnouncementsQyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
3M ago
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
Premium
Company Announcements
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
4M ago
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
Premium
Company Announcements
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
5M ago
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
PremiumCompany AnnouncementsQyuns Therapeutics Announces EGM to Discuss Key Resolutions
6M ago
Qyuns Therapeutics Announces EGM and H Shares Register Closure
Premium
Company Announcements
Qyuns Therapeutics Announces EGM and H Shares Register Closure
6M ago
Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals
Premium
Company Announcements
Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100